Abstract
Objective: We characterized acquired von Willebrand syndrome (AVWS) among essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Methods: A review of patients with ET or PV evaluated for AVWS.
Results: Of 116 patients with ET, 64 (55%) developed AVWS; of 57 with PV, 28 (49%) developed AVWS. Median platelet counts of ET and PV patients who developed AVWS were 920 X 109/L and 679 X 109/L, respectively (P=0.01). Of patients who developed AVWS, 69.5% had platelet counts below 1000 X 109/L. Bleeding was more common in patients with AVWS, among both ET and PV patients (P<0.001). VWF:RCo levels and VWF:RCo/VWF:Ag ratio were lower among JAK2 V617F positive- vs. JAK2 V617F negative- ET patients (P=0.02 and P=0.002, respectively); whereas VWF:Ag levels were comparable (P=0.96). ET patients harboring the JAK2 V617F mutation were more likely to develop AVWS than were calreticulin-positive patients (70.3% vs. 45.7%, P=0.02), despite lower platelet counts (median 773 vs. 920 X 109/l, P=0.05). In multivariable analysis, age (β=0.26, P=0.002), platelet count (β=-0.38, P<0.001), hemoglobin level (β=-0.22, P=0.01) and JAK2 V617F mutation (β=-0.23, P=0.01) independently predicted VWF:RCo, among ET patients; whereas only platelet count predicted VWF:RCo among PV patients (β=-0.49, P<0.001).
Conclusion: Among ET and PV patients, AVWS was common and associated with higher bleeding rates and higher platelet count; nonetheless, most AVWS patients had platelet counts under 1000 X 109/L. Thus, AVWS screening should be included in routine assessment of ET and PV patients. Among ET patients, JAK2 V617F was a main driver for the development of AVWS.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/22/10.1182_blood.v128.22.5466.5466/3/m_inf01.gif?Expires=1724161089&Signature=mXW-04U5G8Et0gVbmjBProxxShCMg-Fb7tE4T0yQtBD9zkD71b7ZdYInXT7Kh7u6tXxZ3wHtnjFYSXJ6bWmSPOg4EBIfpsl-koapyAgOw2Lm2Ksrx7~J1z9Ue--RfT4rTWtlcXDbNnJyqlnoipqhV1zKccJ75dHCdXMBShvUyQnrxvvrxeyoDlKpvtz1P6WeYEbcpv41g5cI2mUt75xGP1z4hZ7E1M6eHz5iUvaUbz3-Eg7PSJMU4IY~wnvMbZ7fYVvUp7M-vxFLS7anKiphiIZCQP2va2pXzPtRwNdWLxEncSd9rOkDcVJwX~cxAj8bIgLl6qQfgDuoN4WxOJWJcA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal